About this trial
This study aims to validate the clinical performance of a newly developed isothermal nucleic acid amplification bioassay module for EBOV. A retrospective studies will be conducted using biobanked patient samples such as plasma samples and buccal swabs already collected by the Institut National de Recherches Biomédicales (INRB) in Kinshasa, DRC as part of their surveillance and outbreak activities. The diagnostic sensitivity and specificity of the EBOV bioassay module will be compared to the gold-standard reverse transcriptase polymerase chain reaction (RT-PCR) technologies used in the national reference lab.
Eligibility criteria
Qualifiers
EBOV test positive and negative biobanked patient samples
Disqualifiers
not applicable
Trial design
Treatments tested in this trial
- DECIPHER bioassay
Treatment groups
Locations
Sponsors and collaborators
Institute of Tropical Medicine, Belgium
Lead sponsor
Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo
Collaborator